ABL1 Fusion

CI-VAR-00001158Explore in graph →CIViC 1

Curated evidence

Evidence by cancer (464 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 351–400 of 464 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive50
BCR::ABL1 Fusion AND ABL1 T315A	Dasatinib	Predictive	D	Supports Resistance	3	accepted	EID6190 In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC) PMID 15705718 · Burgess et al., 2005 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 T315I	(prognostic)	Prognostic	B	Supports Better Outcome	4	submitted	EID8044 T315I is an unfavorable mutation in the BCR-ABL1translocation leading to Chronic Myeloid Leukemia. In this article, experts review and compile the literature regarding the use of Ponatinib (a tyrosine… (full text at CIViC) PMID 31590170 · Saussele et al., 2020 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.